Expert Interview
A third view: Digging into the P1/2 results and potential of Relay Therapeutics' FGFR2 inhibitor, RLY-4008, in cholangiocarcinoma.
Ticker(s): RLAY, INCY, Taiho Pharmaceuticals, QED TherapeuticsInstitution: Zangmeister Cancer Center
- Board certified in Oncology and Hematology and is a member of American Society of Clinical Oncology, American Association for Cancer Research, and International Society of Gastrointestinal Oncology.
- Research focuses on improving patient outcomes using targeted therapies and genomic medicine including clinical research at The Zangmeister Cancer Center.
- Evaluates and treats all blood and cancer disorder with a special interest in gastrointestinal cancers
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
